HBV
MCID: HPT016
MIFTS: 63

Hepatitis B (HBV)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatitis B

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 11 75 53 41 43 14 36 71
Hepatitis B Infection 11 14
Chronic Hepatitis B 11 33
Chronic Hbv - [hepatitis B Virus] Infection 33
Chronic Hepatitis B Without Delta Agent 33
Chronic Type B Viral Hepatitis 33
Hbv, Susceptibility to 5
Hepatitis B, Chronic 71
Hepatitis B Chronic 53
Serum Hepatitis 11
Hepatitis B Nos 33
Hep B Nos 33
Hbv 47

Classifications:



External Ids:

Disease Ontology 11 DOID:2043
MeSH 43 D006509
NCIt 49 C3097
SNOMED-CT 68 66071002
UMLS 71 C0019163 C0524909

Summaries for Hepatitis B

MedlinePlus: 41 What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis B? Hepatitis B is a type of viral hepatitis. It can cause an acute (short-term) or chronic (long-term) infection. People with an acute infection usually get better on their own without treatment. Some people with chronic hepatitis B will need treatment. Thanks to a vaccine, hepatitis B is not very common in the United States. It is more common in certain parts of the world, such as sub-Saharan Africa and parts of Asia. What causes hepatitis B? Hepatitis B is caused by the hepatitis B virus. The virus spreads through contact with blood, semen, or other body fluids from a person who has the virus. Who is at risk for hepatitis B? Anyone can get hepatitis B, but the risk is higher in: Infants born to mothers who have hepatitis B People who inject drugs or share needles, syringes, and other types of drug equipment Sex partners of people with hepatitis B, especially if they are not using latex or polyurethane condoms during sex Men who have sex with men People who live with someone who has hepatitis B, especially if they use the same razor, toothbrush, or nail clippers Health care and public-safety workers who are exposed to blood on the job Hemodialysis patients People who have lived in or traveled often to parts of the world where hepatitis B is common Have diabetes, hepatitis C, or HIV What are the symptoms of hepatitis B? Often, people with hepatitis B don't have symptoms. Adults and children over 5 are more likely to have symptoms than younger children. Some people with acute hepatitis B have symptoms 2 to 5 months after infection. These symptoms can include: Dark yellow urine Diarrhea Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Abdominal pain Yellowish eyes and skin, called jaundice If you have chronic hepatitis B, you may not have symptoms until complications develop. This could be decades after you were infected. For this reason, hepatitis B screening is important, even if you have no symptoms. Screening means that you are tested for a disease even though you don't have symptoms. If you are at high risk, your health care provider may suggest screening. What other problems can hepatitis B cause? In rare cases, acute hepatitis B can cause liver failure. Chronic hepatitis B can develop into a serious disease that causes long-term health problems such as cirrhosis (scarring of the liver), liver cancer, and liver failure. If you have ever had hepatitis B, the virus may become active again, or reactivated, later in life. This could start to damage the liver and cause symptoms. How is hepatitis B diagnosed? To diagnose hepatitis B, your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam Blood tests, including tests for viral hepatitis What are the treatments for hepatitis B? If you have acute hepatitis B, you probably don't need treatment. Some people with chronic hepatitis B don't need treatment. But if you have a chronic infection and blood tests show that hepatitis B could be damaging your liver, you may need to take antiviral medicines. Can hepatitis B be prevented? The best way to prevent hepatitis B is to get the hepatitis B vaccine. You can also reduce your chance of hepatitis B infection by: Not sharing drug needles or other drug materials Wearing gloves if you have to touch another person's blood or open sores Making sure your tattoo artist or body piercer uses sterile tools Not sharing personal items, such as toothbrushes, razors, or nail clippers Using a latex condom during sex. If your or your partner is allergic to latex, you can use polyurethane condoms. If you think you have been in contact with the hepatitis B virus, see your health care provider right away. Your provider may give you a dose of the hepatitis B vaccine to prevent infection. In some cases, your provider may also give you a medicine called hepatitis B immune globulin (HBIG). You need to get the vaccine and the HBIG (if needed) as soon as possible after coming into contact with the virus. It is best if you can get them within 24 hours. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hepatitis B, also known as hepatitis b infection, is related to hepatitis and hepatitis d, and has symptoms including fever, nausea and vomiting and constipation. An important gene associated with Hepatitis B is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Overview of interferons-mediated signaling pathway. The drugs Glycyrrhizic acid and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are neoplasm and endocrine/exocrine gland

Disease Ontology: 11 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, blood transfusions, or fomites like needles or syringes. The infection has symptom fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, clay-colored bowel movements, joint pain, and jaundice.

Wikipedia: 75 Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1572)
# Related Disease Score Top Affiliating Genes
1 hepatitis 33.3 SLC10A1 RSF1 NR5A2 LAMTOR5 IFNA2 IFNA1
2 hepatitis d 33.2 SLC10A1 IFNA2 IFNA1 GPT
3 viral hepatitis 33.0 IFNA2 IFNA1 GPT F2 ALB AFP
4 liver cirrhosis 32.8 IFNA1 GPT F2 ALB AFP
5 viral infectious disease 32.7 MIR21 IFNAR2 IFNA2 IFNA1 GPT
6 hepatitis a 32.7 IFNA2 IFNA1 GPT F2 ALB AFP
7 liver disease 32.6 SLC10A1 MIR21 IFNA2 IFNA1 GPT F2
8 hepatitis c 32.5 IFNAR2 IFNA2 IFNA1 GPT F2 AFP
9 hepatic encephalopathy 31.9 GPT F2 ALB
10 hepatitis e 31.9 GPT F2 ALB
11 alcohol use disorder 31.8 GPT F2 ALB AFP
12 portal hypertension 31.7 GPT F2 ALB AFP
13 cryoglobulinemia 31.6 IFNA2 IFNA1 GPT
14 alcoholic liver cirrhosis 31.6 GPT F2 ALB AFP
15 schistosomiasis 31.6 IFNGR1 GPT F2 ALB
16 esophageal varix 31.6 GPT F2 ALB AFP
17 hepatocellular carcinoma 31.6 RSF1 MIR301A MIR21 MIR17 IFNAR2 IFNA2
18 exanthem 31.5 IFNA1 GPT F2 ALB
19 cryoglobulinemia, familial mixed 31.5 IFNA2 IFNA1
20 hepatorenal syndrome 31.5 GPT F2 ALB AFP
21 deficiency anemia 31.5 IFNA2 IFNA1 GPT F2 ALB
22 portal vein thrombosis 31.5 GPT F2 ALB AFP
23 chickenpox 31.5 IFNA1 GPT F2 ALB
24 autoimmune hepatitis 31.5 GPT F2 ALB
25 bilirubin metabolic disorder 31.4 SLC10A1 GPT F2 ALB AFP
26 non-alcoholic steatohepatitis 31.4 MIR21 GPT ALB AFP
27 immune deficiency disease 31.3 MIR21 MIR17 IFNGR1 IFNA1 GPT APOBEC3G
28 rubella 31.3 IL10RB IFNAR2 GPT
29 thrombocytopenia 31.3 MIR21 IFNA2 IFNA1 GPT F2 ALB
30 hypothyroidism 31.3 IFNA2 IFNA1 GPT F2 ALB AFP
31 intrahepatic cholestasis 31.3 GPT ALB AFP
32 hepatic coma 31.2 GPT F2 ALB AFP
33 dengue disease 31.2 IFNA1 GPT ALB
34 acute kidney failure 31.2 GPT F2 ALB
35 substance abuse 31.2 GPT F2 ALB AFP
36 cholangitis 31.2 GPT F2 ALB
37 hypersplenism 31.2 GPT F2 ALB AFP
38 intrahepatic cholestasis of pregnancy 31.1 SLC10A1 NR5A2 GPT
39 alcoholic hepatitis 31.1 GPT F2 ALB
40 cholecystitis 31.1 GPT F2 ALB
41 hemochromatosis, type 1 31.1 GPT F2 ALB AFP
42 malaria 31.1 IFNGR1 IFNA2 IFNA1 GPT F2 ALB
43 drug-induced hepatitis 31.1 GPT F2 ALB AFP
44 diarrhea 31.0 IFNA2 IFNA1 GPT ALB
45 biliary atresia 31.0 SLC10A1 GPT F2 ALB
46 neutropenia 31.0 IFNA2 IFNA1 GPT ALB
47 intrahepatic cholangiocarcinoma 31.0 MIR17 ALB AFP
48 hyperthyroidism 30.9 GPT F2 ALB
49 budd-chiari syndrome 30.9 GPT F2 ALB AFP
50 primary biliary cholangitis 30.9 SLC10A1 MIR17 GPT F2 ALB AFP

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

11
  • fever

UMLS symptoms related to Hepatitis B:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis B:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.7 AFP AIP ALB APOBEC3G IFNAR2 IFNGR1
2 endocrine/exocrine gland MP:0005379 9.65 AFP AIP ALB DDB1 F2 IFNGR1
3 mortality/aging MP:0010768 9.47 AIP ALB APOBEC3G CPD DDB1 F2

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
2
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
3
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
4
Tocopherol Approved, Investigational Phase 4 1406-66-2
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
7
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
8
Lenograstim Approved, Investigational Phase 4 135968-09-1
9
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
10
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
11
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
12
Simethicone Approved Phase 4 8050-81-5
13
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
14
Ribavirin Approved Phase 4 36791-04-5 37542
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Iron Approved Phase 4 7439-89-6 29936
17
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
18
Pentetic acid Approved Phase 4 67-43-6
19
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
20
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
21
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
22
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
23
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
24
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
25
Calcium carbonate Approved, Investigational Phase 4 471-34-1
26
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
27
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 4 8002-43-5, 1446756-47-3, 18656-38-7 26197 9547096 6323481
28
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
29
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
30
Racemethionine Approved, Experimental, Investigational, Nutraceutical Phase 4 59-51-8, 63-68-3, 348-67-4 6137
31
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 4 133585-56-5, 60-18-4, 556-02-5 1153 6057
32
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
33
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
34
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 4 461-06-3
35
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
36
Tocotrienol Investigational Phase 4 6829-55-6 9929901
37
Thymalfasin Investigational Phase 4 62304-98-7 16167214 16130571
38 Oxymatrine Investigational Phase 4 16837-52-8
39
Clevudine Investigational Phase 4 163252-36-6
40 Neurotransmitter Agents Phase 4
41 Anesthetics Phase 4
42 Protective Agents Phase 4
43 Chlorhexidine gluconate Phase 4
44 Antimetabolites Phase 4
45 Antitubercular Agents Phase 4
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
47 Polyene phosphatidylcholine Phase 4
48 Essential 303 forte Phase 4
49 Antihypertensive Agents Phase 4
50 Hypolipidemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1560)
# Name Status NCT ID Phase Drugs
1 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
2 Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Unknown status NCT01907230 Phase 4 Entecavir
3 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
4 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
5 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
6 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
7 Maintaining Antiviral Efficacy After Switching to Generic Entecavir, Baracle® in Patients Taking Baraclude® 1 mg for Antiviral Resistant Chronic Hepatitis B; A Noninferiority Study Assessing Non-detection Rate of Hepatitis B Virus DNA Unknown status NCT04069858 Phase 4 Switching to Generic Entecavir (Baracle®)
8 Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood Unknown status NCT01341275 Phase 4
9 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
10 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
11 The Effect of Entecavir Consolidation on Post-TDF Treatment Durability Unknown status NCT03308890 Phase 4 0.5mg Baraclude(entecavir)
12 Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes Unknown status NCT04584242 Phase 4 gluconon tab 15mg;suganon tab 5mg
13 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
14 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
15 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
16 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
17 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
18 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
19 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
20 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
21 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
22 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
23 A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B Unknown status NCT03357822 Phase 4 Pegylated interferon;Entecavir;Tenofovir disoproxil fumarate
24 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
25 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
26 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
27 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
28 Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
29 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
30 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
31 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
32 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
33 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
34 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
35 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
36 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;essentiale + entecavir;Vitamin E + entecavir
37 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
38 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
39 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
40 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
41 An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase Unknown status NCT02463019 Phase 4 Tenofovir Disoproxil Fumarate
42 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
43 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
44 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
45 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
46 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
47 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
48 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
49 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
50 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETV;TDF;ADV;Peginterferon Alfa-2a

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 71 / NDF-RT 50 :


adefovir
adefovir dipivoxil
entecavir
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
Interferon Alfa-2b
Lamivudine
telbivudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

Organs/tissues related to Hepatitis B:

FMA: Liver
MalaCards : Liver, Kidney, T Cells, Bone Marrow, Skin, Placenta, Bone

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 42147)
# Title Authors PMID Year
1
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 53 62 5
19488747 2009
2
Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. 62 5
16757563 2006
3
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 5
16690980 2006
4
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 5
12516030 2003
5
Hepatitis B and C viral coinfections and their association with HIV viral load suppression among HIV-1 infected patients on ART at Mekelle hospital, northern Ethiopia. 41
36457041 2022
6
Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: a systematic review of reported outbreaks between 2006 and 2021. 41
36463162 2022
7
Hepatitis B functional cure and immune response. 41
36466821 2022
8
Plasma levels of trace elements have an implication on interferon treatment of children with chronic hepatitis B infection. 53 62
19727570 2010
9
T29C genotype polymorphism of estrogen receptor alpha is associated with initial response to interferon-alpha therapy in chronic hepatitis B patients. 53 62
20525555 2010
10
Effect of maternal hepatitis B carrier status on first-trimester markers of Down syndrome. 53 62
20332164 2010
11
Viral hepatitis and inflammatory bowel disease. 53 62
20480515 2010
12
Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. 53 62
20304099 2010
13
Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. 53 62
20038212 2010
14
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. 53 62
20176893 2010
15
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 53 62
20155784 2010
16
Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. 53 62
20419804 2010
17
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? 53 62
20162620 2010
18
Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes. 53 62
20164184 2010
19
Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. 53 62
20070399 2010
20
Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. 53 62
20107884 2010
21
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. 53 62
20044806 2010
22
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 53 62
20357999 2010
23
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. 53 62
20028815 2010
24
Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. 53 62
19857525 2010
25
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. 53 62
20091678 2010
26
The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. 53 62
20053744 2010
27
A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. 53 62
20137825 2010
28
Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. 53 62
20022949 2010
29
Prevalence and risk factors of focal sparing in hepatic steatosis. 53 62
20157869 2010
30
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. 53 62
20101751 2010
31
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. 53 62
19902424 2010
32
NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. 53 62
20010875 2010
33
Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. 53 62
19900483 2010
34
The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1. 53 62
19958770 2010
35
A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase. 53 62
20126469 2010
36
Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. 53 62
20121403 2010
37
Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. 53 62
19656618 2010
38
Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cells. 53 62
19968784 2010
39
Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. 53 62
19788696 2010
40
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. 53 62
19780875 2010
41
How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? 53 62
19609218 2010
42
Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. 53 62
20030580 2010
43
Occult hepatitis B virus infection: a covert operation. 53 62
20002296 2010
44
Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. 53 62
19853955 2009
45
Distinct regulation of hepatitis B virus biosynthesis by peroxisome proliferator-activated receptor gamma coactivator 1alpha and small heterodimer partner in human hepatoma cell lines. 53 62
19793803 2009
46
Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. 53 62
19833099 2009
47
Peroxisome proliferator-activated receptor gamma Coactivator 1alpha and small heterodimer partner differentially regulate nuclear receptor-dependent hepatitis B virus biosynthesis. 53 62
19793822 2009
48
Nutritional status of children with chronic hepatitis B in a population with low socioeconomic status. 53 62
19458532 2009
49
Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. 53 62
19752878 2009
50
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 53 62
19797428 2009

Variations for Hepatitis B

ClinVar genetic disease variations for Hepatitis B:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IFNGR1 NM_000416.3(IFNGR1):c.-56T>C SNV Risk Factor
355565 rs2234711 GRCh37: 6:137540520-137540520
GRCh38: 6:137219383-137219383
2 IFNAR2 NM_001289125.3(IFNAR2):c.23T>C (p.Phe8Ser) SNV Risk Factor
7288 rs2229207 GRCh37: 21:34614250-34614250
GRCh38: 21:33241945-33241945
3 IL10RB NM_000628.5(IL10RB):c.139A>G (p.Lys47Glu) SNV Risk Factor
16923 rs2834167 GRCh37: 21:34640788-34640788
GRCh38: 21:33268483-33268483
4 IFNAR2 NM_001289125.3(IFNAR2):c.505G>A (p.Val169Ile) SNV Uncertain Significance
1673082 GRCh37: 21:34621124-34621124
GRCh38: 21:33248819-33248819
5 IFNGR1 NM_000416.3(IFNGR1):c.974C>T (p.Pro325Leu) SNV Uncertain Significance
992563 rs753495798 GRCh37: 6:137519664-137519664
GRCh38: 6:137198527-137198527

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.6 MIR301A MIR21 MIR17 IFNAR2 IFNA2 IFNA1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon-mediated signaling pathway GO:0060337 9.85 IFNAR2 IFNA2 IFNA1
2 defense response to virus GO:0051607 9.85 APOBEC3G IFNA1 IFNA2 IFNAR2 IL10RB
3 cytokine-mediated signaling pathway GO:0019221 9.65 IL10RB IFNGR1 IFNAR2 IFNA2 IFNA1
4 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.58 MIR301A MIR21 MIR17
5 cellular response to virus GO:0098586 9.36 MIR21 IL10RB IFNGR1 IFNAR2 IFNA2 IFNA1
6 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.32 MIR21 MIR17
7 positive regulation of metalloendopeptidase activity GO:1904685 9.26 MIR21 MIR17

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor activity GO:0004896 9.1 IL10RB IFNGR1 IFNAR2

Sources for Hepatitis B

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....